Stay updated with breaking news from Markus Warmuth. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
MRT-6160, a VAV1-directed molecular glue degrader , inhibits colitis disease progression and colon inflammation, lowers inflammatory mucosal cytokines, and reduces expression of IBD-associated genes...
#Tu1727: MRT-6160, a VAV1-Directed Molecular Glue Degrader, Inhibits Disease Progression in a T-cell Transfer Mediated Colitis Model Concomitant with Reduced Calprotectin...
02.05.2024 - Dr. Wallace will depart his role as CSO effective May 17, 2024, and will serve as a scientific advisor, including on Monte Rosa’s Scientific Advisory BoardBOSTON, Mass., May 02, 2024 (GLOBE NEWSWIRE) - Monte Rosa Therapeutics, Inc. (Nasdaq: GLUE), ... Seite 1
Phase 1/2 clinical trial of MRT-2359 in MYC-driven solid tumors on track; recommended Phase 2 dose expected in Q2 2024 Received US FDA Fast Track Designation for MRT-2359 for previously...
MRT-2359 had acceptable tolerability with a favorable pharmacokinetic and pharmacodynamic profile in heavily pretreated patients with MYC-driven solid tumors, including lung cancer and high-grade neuroendocrine cancer.